Active suppression of tumor-specific T lymphocytes can limit the efficacy of immune surveillance and immunotherapy. While tumor-recruited CD11b+ myeloid cells are known mediators of tumor-associated immune dysfunction, the true nature of these suppressive cells and the fine biochemical pathways governing their immunosuppressive activity remain elusive. Here we describe a population of circulating CD11b+IL-4 receptor α+ (CD11b+IL-4Rα+), inflammatory-type monocytes that is elicited by growing tumors and activated by IFN-γ released from T lymphocytes. CD11b+IL-4Rα+ cells produced IL-13 and IFN-γ and integrated the downstream signals of these cytokines to trigger the molecular pathways suppressing antigen-activated CD8+ T lymphocytes. Analogous immunosuppressive circuits were active in CD11b+ cells present within the tumor microenvironment. These suppressor cells challenge the current idea that tumor-conditioned immunosuppressive monocytes/macrophages are alternatively activated. Moreover, our data show how the inflammatory response elicited by tumors had detrimental effects on the adaptive immune system and suggest novel approaches for the treatment of tumor-induced immune dysfunctions.
Giovanna Gallina, Luigi Dolcetti, Paolo Serafini, Carmela De Santo, Ilaria Marigo, Mario P. Colombo, Giuseppe Basso, Frank Brombacher, Ivan Borrello, Paola Zanovello, Silvio Bicciato, Vincenzo Bronte
Title and authors | Publication | Year |
---|---|---|
Macrophages are activated towards phagocytic lymphoma cell clearance by pentose phosphate pathway inhibition
Anna C. Beielstein, Elena Izquierdo, Stuart J Blakemore, Nadine Nickel, Michael Michalik, Samruddhi Chawan, Reinhild Brinker, Hans-Henrik Bartel, Daniela Vorholt, Janica Nolte, Rebecca Linke, Carolina Raissa Costa Picossi, Jorge Sáiz, Felix Picard, Alexandra Florin, Jörn Meinel, Reinhard Büttner, Alma Villaseñor, Holger Winkels, Michael Hallek, Marcus Krüger, Coral Barbas, Christian Pallasch |
Cell reports. Medicine | 2024 |
Immune Escape Strategies in Head and Neck Cancer: Evade, Resist, Inhibit, Recruit.
Kostecki KL, Iida M, Crossman BE, Salgia R, Harari PM, Bruce JY, Wheeler DL |
Cancers | 2024 |
High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-Hodgkin lymphoma patients treated with R-CHOP
Dhar S, Chakravarti M, Ganguly N, Saha A, Dasgupta S, Bera S, Sarkar A, Roy K, Das J, Bhuniya A, Ghosh S, Sarkar M, Hajra S, Banerjee S, Pal C, Saha B, Mukherjee KK, Baral R, Bose A |
Frontiers in immunology | 2024 |
Exosomes—Promising Carriers for Regulatory Therapy in Oncology
Jóźwicka TM, Erdmańska PM, Stachowicz-Karpińska A, Olkiewicz M, Jóźwicki W |
Cancers | 2024 |
IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma
Montoya M, Collins SA, Chuntova P, Patel TS, Nejo T, Yamamichi A, Kasahara N, Okada H |
2024 | |
Pre-Existing Immunity Predicts Response to First-Line Immunotherapy in Non-Small Cell Lung Cancer Patients
Xagara A, Goulielmaki M, Fortis SP, Kokkalis A, Chantzara E, Christodoulopoulos G, Samaras I, Saloustros E, Tsapakidis K, Papadopoulos V, Pateras IS, Georgoulias V, Baxevanis CN, Kotsakis A |
Cancers | 2024 |
Myeloid‑derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in colorectal cancer (Review).
Zeng W, Liu H, Mao Y, Jiang S, Yi H, Zhang Z, Wang M, Zong Z |
International journal of oncology | 2024 |
Proliferation of MDSCs may indicate a lower CD4+ T cell immune response in schistosomiasis japonica
Peng B, Luo Y, Xie S, Zhuang Q, Li J, Zhang P, Liu K, Zhang Y, Zhou C, Guo C, Zhou Z, Zhou J, Cai Y, Xia M, Cheng K, Ming Y |
Parasite | 2024 |
Targeting amino acid-metabolizing enzymes for cancer immunotherapy
Grobben Y |
Frontiers in Immunology | 2024 |
Prognostic Significance of CD11b-, CD8-, and CD163-Positive Tumor-Infiltrating Immune Cells in Distal Bile Duct Cancer.
Choi JH, Kim JY, Lee KR, Lee GY, Hong M, Hwang HW, Lee MY, Kim MK, Hong SA |
Journal of personalized medicine | 2024 |
Defining myeloid-derived suppressor cells.
Akkari L, Amit I, Bronte V, Fridlender ZG, Gabrilovich DI, Ginhoux F, Hedrick CC, Ostrand-Rosenberg S |
Nature reviews. Immunology | 2024 |
Interferon regulatory factor 8-driven reprogramming of the immune microenvironment enhances antitumor adaptive immunity and reduces immunosuppression in murine glioblastoma
Montoya M, Collins SA, Chuntova P, Patel TS, Nejo T, Yamamichi A, Kasahara N, Okada H |
Neuro-Oncology | 2024 |